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Dimke H, Flyvbjerg A, Bourgeois S, Thomsen K, Frøkiær J,
Houillier P, Nielsen S, Frische S. Acute growth hormone adminis-
tration induces antidiuretic and antinatriuretic effects and in-
creases phosphorylation of NKCC2. Am J Physiol Renal Physiol
292: F723–F735, 2007. First published October 24, 2006;
doi:10.1152/ajprenal.00276.2006.—Growth hormone (GH) has anti-
diuretic and antinatriuretic effects in rats and humans, but the molec-
ular mechanisms responsible for these effects are unknown. The aim
of this study was to investigate the mechanisms behind the acute renal
effects of GH in rats. Female rats received rat (r)GH (2.8 mg/kg sc) or
saline and were placed in metabolic cages for 5 h. Urinary excretion
of electrolytes and urinary volume were reduced after rGH injection,
while urine osmolality was increased. Creatinine and lithium clear-
ance remained unchanged, suggesting that rGH increases reabsorption
in segments distal to the proximal tubule. Total plasma insulin-like
growth factor I (IGF-I) levels did not change, while cortical IGF-I
mRNA abundance was increased. The relative abundance of total and
Ser256-phosphorylated aquaporin 2 was found to be unchanged by
immunoblotting, whereas a significant increase of Thr96 and Thr101-
phosphorylated NKCC2 (renal Na, K, 2Cl cotransporter) was
found in the inner stripe of outer medulla thick ascending limbs
(mTAL). Additionally, an increased NKCC2 expression was observed
in the cortical region. Immunohistochemistry confirmed these find-
ings. The density of NKCC2 molecules in the apical membrane of
mTAL cells appeared to be unchanged after rGH injection evaluated
by immunoelectron microscopy. Basolateral addition of rGH or IGF-I
to microperfused rat mTAL segments did not change transepithelial
voltage. In conclusion, GH appears to exert its acute antinatriuretic
and antidiuretic effects through indirect activation of NKCC2 in the
mTAL.
thick ascending limb; sodium; insulin-like growth factor I; GH;
kidney
GROWTH HORMONE (GH) is secreted in a pulsatile pattern by the
anterior pituitary (8) and has a number of well-known effects
including stimulation of bone growth (28) and change in body
composition (53). While disturbance of normal growth is a
hallmark of abnormal GH secretion, these patients also present
with a distorted sodium and water homeostasis. Hypersecretion
of GH in acromegaly is associated with a larger extracellular
volume (ECV) (27), and patients suffering from GH deficiency
have a decreased ECV (52), which can be augmented by GH
replacement therapy (4). Similarly, chronic administration of
GH expands ECV (40) and decreases sodium excretion in
healthy humans (21, 25, 31) and rats (63). The decrease in
sodium excretion is often transient, only occurring within the
initial period of GH administration (2, 3, 25, 31, 58).
Since sodium retention is only seen transiently in studies of
chronic GH treatment, compensatory changes counteracting
the antinatriuretic and antidiuretic effects of GH may be
induced after a few days of GH treatment leading to a new
steady state of sodium balance, albeit in some cases with
expanded ECV. Moreover, GH-induced stimulation of other
renotrophic hormones may also contribute to maintaining the
expanded ECV. To understand the renal aspects of the complex
state of chronic GH treatment, it is therefore necessary to
dissect the changes in renal function into acute changes fol-
lowing shortly after a single GH injection and chronic (includ-
ing compensatory) changes seen only upon repeated injections
or similar chronic treatment.
In comparison to chronic GH administration, the initial
(acute) effects of GH on renal water and sodium handling have
been less studied. The available studies in humans report an
acute decrease in urinary sodium excretion, within the first day
of GH administration (2, 3). In rats, the acute antinatriuretic
and antidiuretic effects of GH are more noticeable. Within few
hours after a bolus injection of GH, a decrease in urinary
volume and urinary electrolyte excretion is observed (32, 36,
54, 56). The pulsatile pattern of GH secretion in conjunction
with the acute antinatriuretic and antidiuretic actions of the
hormone suggests that GH is important, not only in pathophys-
iological states, but also as a component in the normal regu-
lation of water and sodium balance, including a possible
regulatory role in the circadian blood pressure rhythm (49).
The changes in renotrophic hormones seen in response to
chronic GH administration have led to the investigation of
these hormones as the prime mediators of the sodium- and
water-retaining effects of GH. Chronic exposure to GH in-
creases circulating and local insulin-like growth factor (IGF-I)
production in healthy humans (21, 40, 41) and GH-deficient
patients (4). However, the direct tubular actions of IGF-I are
incompletely understood (23, 24). Several attempts to clarify
the function of the renin-angiotesin-aldosterone (RAA) system
in the antinatriuretic response observed after chronic GH ad-
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ministration have also been made. However, the results are
contradictory as some studies report an increased activity of
one or more components of the RAA system, while other
studies conclude differently (1, 21, 22, 25, 31, 41). Other
hormones such as vasopressin (AVP) and atrial natriuretic
factor have also been suspected to be involved in mediating the
GH-induced antinatriuresis, but no changes were found in AVP
concentrations (25, 40) and contradictory findings were ob-
served regarding atrial natriuretic factor (21, 41). These studies
were based on protocols of chronic GH exposure and thus do
not address whether these hormones are involved in the pri-
mary effect of GH or in compensatory changes following
prolonged GH treatment. Very few studies have investigated
the acute effect of GH on renotrophic hormonal systems. In
humans and rats, no change in plasma renin activity was seen
after a bolus injection of GH (10, 26). Additionally, adrenal-
ectomized rats receiving GH for 3 days show an immediate
decrease in sodium excretion, in the same manner as normal
rats (58). These studies indicate that the classical RAA system
is not activated as part of the acute effect of GH.
To determine the mechanisms behind the acute effects of
GH on electrolyte and water excretion, we decided to 1)
investigate the effects of rat GH (rGH) on renal reabsorption of
sodium, potassium, chloride, and water in rats during the first
5 h after a single rGH injection, 2) determine in which parts of
the renal tubule rGH exerts its antinatriuretic and antidiuretic
effects using lithium clearance, 3) determine whether the
circulating and renal concentrations of IGF-I were changed 5 h
after a single rGH injection to assess whether the observed
effects were due to a direct action of GH or indirectly through
stimulation of IGF-I, 4) investigate the molecular mechanisms
behind the observed renal effects by determining the expres-
sion levels, phosphorylation levels (applying antibodies against
the phosphorylated forms), and subcellular localization of the
AVP-regulated water channel aquaporin 2 (AQP2) and the
bumetanide-sensitive Na, K, Cl-cotransporter (NKCC2)
using immunoblotting, immunohistochemistry and immuno-
electronmicroscopy, and 5) determine whether the observed
effects were directly mediated by rGH using the microperfused
isolated tubuli system.
METHODS
Experimental animals. Animal experiments were performed fol-
lowing the Danish and French legislations on animal experiments and
according to license number 2004/561–816 for use of experimental
animals issued by the Danish Ministry of Justice and to licence
number A75–06-10 for use of experimental animals issued by the
Paris city Police Headquarters. Animals for experimental protocols
1-3 were acquired from Taconic (M&B Ry, Denmark).
Experimental protocol 1. Twenty-four female Wistar-Hannover
rats, weighing 190–210 g, were placed in metabolic cages 3 days
before the experiment for acclimation. They were maintained on a
standard rodent diet (Altromin 1321, Lage, Germany) with free access
to food and water. On the day of the experiment, rats were divided
randomly into two groups. One group (n  12) received a bolus
injection of rGH (2.8 mg/kg, Novo Nordisk, Gentofte, Denmark),
diluted to a concentration of 1 mg rGH/ml saline. A control group
(n  12) was injected with an equal volume of physiological saline.
Injections were given subcutaneously in the nape of the neck. Just
before the injection, the rats were prompted to empty their bladders by
being placed individually on a plate. Almost all of the rats voided
spontaneously during these conditions (60). The rats were then
weighed and placed in a clean metabolic cage. Five hours later, the
rats were opened by a large laparotomy under halothane inhalation
(3%, 5 l/min, Halocarbon laboratories). The bladder was emptied
using a syringe and the content was pooled with the previously
collected urine. The kidneys were either removed and dissected into
zones [cortex/outer stripe of outer medulla (CTX/OSOM), inner stripe
of outer medulla (ISOM), and inner medulla (IM)] for immunoblot-
ting and real-time PCR, or the abdominal aorta was cannulated and the
kidneys were perfusion fixed for immunohistochemical analysis. A
blood sample was withdrawn from the vena cava for further analysis.
Rats were killed with 10-min interval and injections were spaced
accordingly. Water and food consumption and urine production dur-
ing the 5-h protocol were measured. The experiment was repeated to
obtain more blood for analysis and kidneys for immunoblotting and
immunohistochemistry. However, during these repeats, the rats were
not placed in metabolic cages and consequently no urine data were
obtained.
Experimental protocol 2. To investigate whether the effects ob-
served in protocol 1 were due to changes in proximal tubular function,
lithium clearance was used as an estimation of the proximal tubular
sodium and water clearance. Twenty-four female Wistar-Hannover
rats, weighing 200–220 g, were used in this experiment. Six days
before the experiment, rats were placed in metabolic cages and
maintained on a standard rodent diet, with an added sodium content of
200 mmol/kg dry fodder to prevent distal reabsorption of lithium.
Three days before the experiment, the diet was supplemented with a
low dose of lithium (12 mmol/kg dry food). Thirty minutes before the
experiment started, blood was removed from the tail under isofluorane
anaesthesia (3%, 5 l/min, Abbott Scandinavia AB), for analysis of Li
concentrations. The remainder of the experiment was carried out as
experimental protocol 1; however, blood removed during the death
was withdrawn from the abdominal aorta.
Experimental protocol 3. The study was carried out essentially as
experimental protocol 1. However, one group of rats (n  6) received
a bolus injection of human (h)GH (2.8 mg/kg body wt; Norditropin,
Novo Nordisk) diluted in saline, while control rats (n  6) were
injected with a placebo solution (Novo Nordisk) diluted in saline.
Blood was removed for determination of hGH and rGH.
Measurements of solutes and creatinine. Total concentrations of
sodium, potassium, and creatinine in plasma and urinary creatinine
were determined using a Vitros 950 (Johnson and Johnson); total
concentrations of sodium and potassium were determined by atomic
absorption photometry (Eppendorf, FCM6341, Hamburg, Germany)
by the department of Clinical Biochemistry, Clinical Institute, Aarhus
University Hospital. Urinary and plasma concentrations of chloride
(ABL 615, Radiometer, Copenhagen, Denmark) as well as the plasma
and urine osmolality (Advanced Osmometer, model 3900, Advanced
Instruments, Norwood, MA, and Osmomat 030-D, Gonotec, Berlin,
Germany) were determined. The lithium concentration in plasma was
measured using flame emission photometry. Urinary lithium concen-
tration was measured by atomic absorption photometry.
Radioimmunoassays. Total plasma IGF-I levels were determined
after acid-ethanol extraction as previously described (20). Intra- and
interassay coefficients of variation (CVs) were 5 and 10%, respec-
tively. Total plasma 22-kDa hGH was measured by a two-site fluoro-
immunometric assay against two antigenic determinants on the 22-
kDa hGH molecule with europium as the reporter molecule (Delfia,
Wallac Oy, Turku, Finland). The level of detection is 0.03 mU/l. The
intra- and interassay CVs at 0.5 mU/l were 5 and 8%, respectively
(57). Plasma rGH was measured by RIA using a specific polyclonal
rabbit rGH antibody and rGH as standard. The materials, including
I125-labeled rGH, were obtained from Amersham (Amersham Inter-
national, Bucks, UK). Intra- and interassay CVs were 5 and 10%,
respectively (20). Serum insulin was measured using a rat insulin
ELISA Kit (DRG Diagnostics, Marburg, Germany), with intra- and
interassay CVs 5 and 10%, respectively.
F724 ACUTE ANTIDIURETIC AND ANTINATRIURETIC ACTIONS OF GH
AJP-Renal Physiol • VOL 292 • FEBRUARY 2007 • www.ajprenal.org
 o
n






Real-time PCR. The method was performed as described previ-
ously (30). Briefly, total cellular RNA was extracted from kidney
zones using 6100 Nucleic Acid PrepStation kit (Applied Biosystems).
RNA was reverse transcribed using Multiscribe Reverse Transcriptase
kit (Applied Biosystems). cDNA products were amplified by PCR by
adding the cDNA to a Taq polymerase mixture (TaqMan Universal
PCR MasterMix), with gene-specific primers against IGF-I
(Rn00710306_m1) and the internal standard eukaryotic 18s rRNA
(Hs99999901_s1) developed by Applied Biosystems. PCR products
were detected by the cleavage of a TaqMan probe annealing to the
product.
Primary antibodies. For semiquantitative immunoblotting, the fol-
lowing affinity-purified polyclonal antibodies were used. 1) Rabbit
polyclonal LL320 AP was a generous gift from Dr. M. Knepper
(National Institutes of Health, Bethesda, MD) and has been exten-
sively characterized earlier (34). 2) Anti-p-NKCC2 9934 AP: this
rabbit polyclonal antibody was raised against a phosphorylated
epitope on NKCC2, earlier described in mice (16). The sequence
stems from the NH2 terminal of NKCC2 and corresponds to amino
acids 91–106 in rat NKCC2 with threonine phosphorylations on Thr96
and Thr101. The antibody was developed by immunizing a rabbit with
the phosphorylated peptide (YYLQTPO3FGHNTPO3MDAVP). The
antiserum was run through a column containing the corresponding
nonphosphorylated peptide, plus an NH2-terminal cysteine for conju-
gation (SulfoLink Antibody Immobilization kit, Pierce). The unbound
fraction was then placed on a column containing the phosphorylated
peptide, plus an NH2-terminal cysteine (SulfoLink). The eluted frac-
tion from the column containing immobilized phosphorylated peptide
was used in this study. 3) Anti-AQP2 (H7661 AP): this rabbit
polyclonal antibody has been developed against the same epitope as
the previously described LL127 (43). The sequence was derived from
the COOH terminal of AQP2 (amino acids 250–271). The sequence
was EVRRRQSVELHSPQSLPRGSKA (plus an NH2-terminal cys-
teine used for conjugation during affinity purification). The antiserum
was affinity purified against the immunizing peptide. The affinity-
purified antibody recognized both the immunizing peptide, as well as
a peptide including a phosphoserine at position 7, corresponding to
serine 256 in rat AQP2. 4) Phosphorylated-AQP2 (p-AQP2) (AN244-
pp-AP): an affinity-purified rabbit polyclonal antibody to serine 256
phosphorylated AQP2 has previously been described (7). 5) Calbindin
(RDI-CALBINDabm): a monoclonal antibody against rat Calbindin
was obtained from Research Diagnostics.
Preparation of tissue for semiquantitative immunoblotting. Kidney
zones were placed in dissection buffer (0.3 M sucrose, 25 mM
imidazole, 1 mM EDTA, pH 7.29), containing inhibitors against
proteases and phosphatases (8.4 M leupeptin, 4 mM pefablock, 100
nM okadaic acid, 25 nM sodium floride, and 1 mM sodium orthovana-
date). The tissue was homogenized (Ultra turrax, T8 homogenizer,
IKA labortechnik, Staufen, Germany) and centrifuged at 4,000 g for
15 min at 4°C (Beckman L8M). The samples were then solubilized in
a SDS-containing sample buffer (final concentration in sample; 62.5
mM Tris, 3% SDS, 8.7% glycerol, 90 M bromphenolblue, and 97.2
mM dithiothreitol) at 95°C for 10 min.
Electrophoresis and semiquantitative immunoblotting. Samples ad-
justed for protein concentration were run on 7.5–15% polyacrylamide
minigels (Bio-Rad Mini Protean II) and transferred to nitrocellulose or
PVDF membranes (Hybond-ECL or Hybond-P, Amersham Pharma-
cia Biotech, Little Chalfont, UK) by electroelution (0.025 M Tris, 0.19
M glycine, and 20% methanol, pH 8.3, 100 V, 1 h). The membranes
were blocked using 5% skimmed milk in a PBS-T solution (80 mM
Na2PO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20, pH 7.5),
washed, and incubated in primary antibody overnight at 4°C. The
labeling was visualized using a horseradish peroxidase (HRP)-conju-
gated secondary antibody (P448, DAKO, Glostrup, Copenhagen,
Denmark) and an enhanced chemiluminescence system (ECL) ex-
posed to photographic film (Hyperfilm ECL). ECL films were scanned
using an AGFA scanner (DUOSCAN f40). The densities of the bands
were determined, using specific quantification software (Scion Image,
Scion, Windows version of NIH-Image). Two-dimensional rolling
ball background subtraction, and the Gel-plot2 macro, was used for
the densitometric analysis.
Differential centrifugation. Kidney slices from the ISOM was
homogenized and centrifuged at 1,000 g for 10 min. The supernatant
was removed and pelleted at 4,000 g for 20 min. The pellet was
rehomogenized and recentrifuged at 4,000 g for 20 min and subse-
quently resuspended in sample buffer. The 4,000-g supernatant was
pelleted at 17,000 g for 30 min, rehomogenized, and recentrifuged at
17,000 g for 30 min and dissolved in sample buffer. The 17,000-g
supernatant was spun at 200,000 g for 60 min. The resulting pellet was
rehomogenized and recentrifuged at the respective speed and time and
processed as above. The fractions, largely consisting of organelles and
nuclei (4,000 g), plasma membranes (17,000 g), and vesicles (200,000
g) were processed for immunoblotting.
Preparation of tissue for light and laser microscopy. Kidneys were
fixed by perfusion (3% paraformaldehyde in 0.1 M sodium cacodylate
buffer, pH 7.4), removed, postfixated for 1 h, and dehydrated before
being embedded in paraffin. Two-micrometer sections were cut from
tissue blocks on a microtome (Leica Microsystems A/S, Herlev,
Denmark).
Single labeling of tissue for light microscopy. Sections were de-
waxed and rehydrated in a series of ethanol. During rehydration,
endogenous peroxidase enzymes were blocked using 0.5% hydrogen
peroxide (H2O2) in absolute methanol. To reveal antigens, sections
were boiled in 10 mM Tris, 0.5 mM EGTA (pH 9.0), using a
microwave oven. To block free aldehyde groups, the sections were
placed in 50 mM NH4Cl in PBS. The sections were then washed in a
0.01 M PBS solution (1% BSA, 0.2% gelatine, and 0.05% saponin)
and incubated overnight at 4°C with primary antibody (0.1% BSA,
0.3% Triton X-100 in PBS). Sections were rinsed in a PBS solution
(0.1% BSA, 0.2% gelatine, 0.05% saponin) and incubated in a
secondary antibody solution (0.1% BSA, 0.3% Triton X-100 in PBS)
containing HRP-conjugated secondary antibodies (P448, DAKO).
Antibody binding was visualized using 3,3-diaminobenzidine (Kem-
En-Tec, Copenhagen, Denmark) in 0.003% H2O2. Sections were
counterstained with Mayer’s hematoxylin, dehydrated, and mounted
using Eukitt reagent (Eukitt, O. Kindler GmbH and Company). Light
microscopy was carried out using a Leica DMRE light microscope
(Leica Microsystems A/S).
Double labeling of tissue for laser confocal microscopy. Sections
were processed as above, except endogenous peroxidases were not
blocked and monoclonal (Calbindin) and polyclonal antibodies (p-
NKCC2 AP) were incubated together overnight. Visualization was
achieved using goat-anti-rabbit and goat-anti-mouse flurophore-con-
jugated secondary antibodies (Alexa488 anti-rabbit, Alexa546 anti-
mouse, highly cross adsorbed, Molecular Probes). Double labeling
was also performed using two polyclonal antibodies (p-NKCC2 and
NKCC2). After incubation with the NKCC2 antibody and the Al-
exa546-conjugated secondary goat anti-rabbit antibody, rabbit IgG
cross-binding was blocked using 10% rabbit serum (dissolved in 0.1%
BSA, 0.3% Triton X-100 in PBS) and endogenous biotin was blocked
using a commercial biotin blocking kit (product no. X0590, DAKO).
Then a second labeling was performed using a primary rabbit anti-
body (p-NKCC2) conjugated to biotin (EZ-Link Sulfo-NHS-LC-
Biotin, product no. 21335, Pierce, Rockford, IL) and secondary
Fluoresein (FITC)-conjugated streptavidin. The microscopy was car-
ried out using a Leica DMIRE2 laser confocal microscope (Leica
Microsystems A/S).
Immunoelectronmicroscopy. Tissue blocks were infiltrated with 2.3
M sucrose, mounted on metal holders, and rapidly frozen in liquid
nitrogen. Frozen tissue blocks were subjected to cryosubstitution and
Lowicryl HM20 embedding. Cryosubstitution was performed as pre-
viously described (38). Ultrathin (45 nm) Lowicryl sections were cut
on a ultramicrotome (Reichert Ultracut S), preincubated with 0.05 M
Tris, 0.1% Triton X-100 (pH 7.4) containing 0.1% sodium borohy-
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dride, and 0.05 M glycine followed by incubation with 0.05 M Tris,
0.1% Triton X-100 (pH 7.4) containing 0.2% skimmed milk. The
preincubation was followed by incubation with affinity-purified anti-
bodies against rat NKCC2 and phosphorylated-NKCC2. Labeling was
visualized with goat anti-rabbit IgG conjugated to 10-nm colloidal
gold particles. Grids were stained with uranyl acetate for 10 min and
with lead citrate for 18 s. Pictures were obtained using a Megaview III
CCD camera (Soft Imaging System). Analysis of NKCC2 membrane
density was done manually by counting gold particles in the mem-
brane (within an area of 30 nm on each side of the membrane) and
dividing it by the length of the membrane studied, which was
measured using an opisometer.
Microperfusion of isolated mTAL segments. Pathogen-free female
Wistar rats weighing 60–75 g (Charles River Laboratories) were
allowed free access to autoclaved standard rat chow and distilled
water until the time of experiments. Rats were anesthetized with 50
mg/kg ip pentobarbital sodium 10 min after injection of 2 mg
furosemide ip to limit medullary thick ascending limb (mTAL)
oxygen consumption during the time of tubule dissection. Both
kidneys were cooled in situ with control bath solution for 1 min and
then removed and cut into thin coronal slices for tubule dissection.
These maneuvers have been shown to improve the viability of renal
tubules in vitro (14, 19). Noteworthy, in vivo intraperitoneal furo-
semide injection does not prevent the ability of NaCl transport in the
mTAL to be subsequently stimulated in vitro by 109 M AVP (P.
Houillier, unpublished results). The mTAL segments were dissected
from the ISOM at 4°C in the control bath solution of the experiment.
The isolated tubule was transferred to the bath chamber on the stage
of an inverted microscope (Axiovert 100, Carl Zeiss, Germany) and
mounted on concentric glass pipettes for microperfusion at 37°C. The
length of the perfused segments ranged from 0.45 to 0.8 mm. The
perfusion (lumen) and bath solutions contained 142 mM Na, 4 mM K,
2 mM Ca, 1.2 mM Mg, 118 mM Cl, 23 mM HCO3, 2 mM lactate, 5
mM HEPES, 1.2 mM SO4, 1 mM citrate, 2 mM HPO4, 5 mM glucose,
and 5 mM alanine. The osmolarity of the solution was 295 5 mosM.
All solutions were equilibrated with 95% O2-5% CO2. pH ranged
from 7.38 and 7.43 at 37°C. The bath solution also contained 0.2%
fraction V bovine serum albumin. Transepithelial voltage (Vte) was
measured with a DP-301 differential electrometer (Warner Instru-
ment, Hamden, CT) by the use of a Ag/AgCl electrode connected to
the perfusion pipette via a 0.15 M NaCl agar bridge; a 0.15 M NaCl
agar bridge also connected the peritubular bath to a Ag/AgCl elec-
trode. Vte was measured during each period at the tip of the perfusion
pipette.
Study protocol. The tubules were equilibrated for 20–30 min at
37°C in the initial perfusion and bath solutions and the luminal flow
was adjusted to 10 nl/min. Three periods were successively performed
on each tubule: initial, experimental, and recovery; after initial re-
cording of Vte, the tubules were exposed to rGH or IGF-I in the bath,
Vte was recorded again and finally Vte was recorded in the absence of
the hormones. The dose of rGH was chosen based on the results of
experimental protocol 3 to match the expected plasma concentration
of rGH in experimental protocol 1. Five hours after hGH injection in
experimental protocol 3, plasma concentration amounted to 8.07 	
109  2.58	 109 M hGH (n 6), while plasma concentrations of
rGH averaged 2.95 	 1010  1.5 	 1010 M rGH (n  6).
Therefore, a concentration of 108 M of rGH was added basolaterally
in these experiments. IGF-I was used at 5 	 108 M, a dose earlier
used in proximal tubules by Quigley and Baum (50).
Calculations of lithium clearance. Renal clearances (C) and frac-
tional excretions (FE) were calculated by the standard formulas as
follows: C U	 V/P; FE C/GFR, where U is urine concentration,
V is the urine flow rate, P is the plasma concentration, and GFR is the
glomerular filtration rate as measured by creatinine clearance. Lithium
clearance (CLi) was calculated as CLi  V 	 ULi/PLi, where PLi 
(PLi, before PLi, after)/2. Fractional Li excretion was calculated as
CLi/CCr, distal fractional Na excretion as CNa/CLi, and distal
fractional water exretion as V/CLi. CLi was used as an index of the
proximal tubular fluid output, and the fractional Li exretion was used
as an index of the fractional delivery of sodium and fluid from the
proximal tubules (58, 60).
Statistical analysis. Values are presented as means  SD and
presented as control vs. GH injected. Comparisons between two
groups were made using an unpaired t-test (P  0.05 is considered
statistically significant).
RESULTS
rGH increases reabsorption of electrolytes and water in
segments distal to the proximal tubule. A bolus injection of
rGH significantly reduced urinary volume (P  0.001) and
raised urinary osmolality (P 0.005) in experimental protocol
1 (Table 1). No differences in food (P  0.82) and water (P 
0.18) intake were observed during the 5-h period. Still, admini-
stration of rGH resulted in a significant reduction in the urinary
excretion of sodium (P 0.0001), potassium (P 0.003), and
chloride (P  0.0002; Table 1). The creatinine clearance
Table 1. Renal function in saline and rGH-injected rats
CON rGH
Experimental protocol 1
Food intake, gkg15 h1 6.14.3 (n12) 6.43.8 (n12)
Water intake, mlkg15 h1 24.89.3 (n12) 32.015.9 (n12)
Urinary output, lmin1kg1 55.320.3 (n12) 30.811.1 (n12)*
Sodium excretion, molmin1kg1 5.651.85 (n12) 2.541.23 (n11)*
Potassium excretion, molmin1kg1 9.502.04 (n12) 6.592.17 (n11)*
Chloride excretion, molmin1kg1 9.612.65 (n12) 5.511.74 (n12)*
Creatinine clearance, mlmin1kg1 3.810.75 (n12) 3.771.09 (n11)
Fractional water excretion, % 1.440.38 (n11) 0.880.37 (n11)*
Fractional Na excretion, % 1.080.24 (n12) 0.490.22 (n10)*
Fractional K excretion, % 6611 (n12) 4613 (n10)*
Fractional Cl excretion, % 2.70.50 (n10) 1.50.47 (n10)*
Urine osmolality, mosmol/kgH2O 1,106207 (n12) 1,509394 (n12)*
Experimental protocol 2
Fractional Li excretion, % 30.113.5 (n11) 30.59.6 (n9)
Distal fractional Na excretion, % 2.430.73 (n11) 0.900.42 (n9)*
Distal fractional water excretion, % 2.380.84 (n11) 1.370.30 (n10)*
Values are presented as means  SD and n represents the number of rats. *P  0.05 is considered statistically significant.
F726 ACUTE ANTIDIURETIC AND ANTINATRIURETIC ACTIONS OF GH
AJP-Renal Physiol • VOL 292 • FEBRUARY 2007 • www.ajprenal.org
 o
n






(estimate of GFR; P  0.91) did not diverge between the
groups (Table 1) and consequently a significant decrease in the
fractional excretion of sodium (P  0.00001), potassium (P 
0.0009), chloride (P  0.00003), and water (P  0.001) was
observed in the rGH-injected group (Table 1). To investigate
whether rGH increases sodium and water reabsorption in the
proximal tubule, an analogous experiment was performed (ex-
perimental protocol 2). In this experiment, dietary sodium was
increased to 200 mmol/kg dry food, and rats received a low
dose of lithium for 3 days. The experiment returned essentially
the same results as experimental protocol 1, i.e., a reduction in
the fractional excretion of electrolytes and urinary volume
(data not shown). The fractional excretion of lithium did not
vary between the rGH- and saline-injected groups (P  0.95).
Thus no difference in the estimated fractional excretion of
sodium and water in the proximal tubule occurs within the 5 h
after rGH injection. The estimated fractional excretion of
sodium (P  0.00003) and water (P  0.002) in segments
distal to the proximal tubule was significantly decreased after
injection of rGH (Table 1).
Changes in circulating and renal IGF-I after rGH injection.
Both circulating and renal production of IGF-I are increased
after chronic GH administration in rats (5, 39). However, little
is known about the dose and time dependency of this response.
In a suspension of collecting ducts IGF-I production occurs
after 2 h of GH incubation in vitro (51), but the acute in vivo
response to GH remains largely unknown. Since acute IGF-I
administration induces antinatriuretic and antikaliuretic effects
(17, 24), circulating and renal production of IGF-I was deter-
mined 5 h after injection of rGH. No difference in plasma
concentrations of total IGF-I was observed between the saline-
injected and rGH-injected group (P  0.31; Table 2). To
investigate whether renal IGF-I production was increased 5 h
after injection of rGH, semiquantitative real-time PCR was
performed on cDNA isolates from renal zones. A significant
increase in IGF-I mRNA abundance was observed in the
CTX/OSOM (P  0.02), while the ISOM (P  0.16) and IM
(P  0.47) showed no change in IGF-I mRNA content (Table
2). Increases in insulin are often observed after GH treatment,
since GH decreases insulin sensitivity (37). As insulin has
direct effects on renal transport mechanisms in rats (11, 29),
insulin levels were measured 5 h after rGH injection. No
change in serum insulin concentration was observed between
the groups (P  0.90; Table 2).
Phosphorylation level and subcellular localization of AQP2
remains unaffected after rGH administration. To investigate
whether the antidiuretic effect of rGH was associated with
increased phosphorylation and subcellular rearrangement of
AQP2, semiquantitative immunoblotting and immunohisto-
chemistry were used. Immunoblots and immunohistochemistry
using anti-phosphorylated-AQP2 (p-AQP2) antibody, selec-
tively recognizing phosphorylated serine 256, revealed no
difference in the phosphorylation level of AQP2 between rats
injected with rGH or saline (Fig. 1, A-B). Moreover, no change
in the total amount of AQP2 was observed in any of the
Fig. 1. Analysis of aquaporin-2 (AQP2) localization, abundance, and phos-
phorylation level. A: immunolabelings of Ser256 phosphorylated-AQP2 (p-
AQP2) on 2-m kidney sections from saline- and rat growth hormone
(rGH)-injected rats. Pictures were obtained through a 	63 objective. Scale
bar  25 m. PT, proximal tubule; CCD, cortical collecting duct. B: semi-
quantitative immunoblots of proteins from the cortex/outer stripe of outer
medulla (CTX/OSOM), inner stripe of outer medulla (ISOM), and inner
medulla (IM) incubated with anti-p-AQP2 antibodies. The graphs represent
p-AQP2 abundance in rGH-injected (open bars) rats as a fraction of the
abundance in saline-injected rats (filled bars). The values are CTX/OSOM:
1.0 0.51 vs. 0.64 0.15, P 0.15; ISOM: 1.0 0.23 vs. 0.85 0.17, P
0.24; and IM: 1.0  0.42 vs. 0.80  0.24, P  0.34. C: semiquantitative
immunoblots of proteins from the CTX/OSOM, ISOM, and IM incubated with
anti-AQP2 antibodies. The graphs represent AQP2 protein abundance in
rGH-injected (open bars) rats as a fraction of the abundance in saline-injected
rats (filled bars). The values are CTX/OSOM: 1.0 0.25 vs. 0.83 0.10, P
0.17; ISOM: 1.0  0.30 vs. 0.73  0.35, P  0.19; and IM: 1.0  0.29 vs.
0.82  0.22, P  0.26. Data are expressed as means  SD and represent n 
6 for each group. The 2 bands with an approximate molecular weight of 28 and
35–50 kDa correspond to the nonglycosylated and glycosylated form of AQP2,
respectively. Both were used for densitometric analyses.
Table 2. Circulating IGF-I, renal IGF-I mRNA expression,
and circulating insulin in saline- and rGH-injected rats
CON rGH
Total IGF-I, g/l 65532.9 (n9) 68685.9 (n10)
Insulin, g/l 1.090.30 (n6) 1.070.25 (n6)
Renal IGF-I mRNA
(fraction of control)
CTX/OSOM 1.000.34 (n6) 2.040.88 (n6)*
ISOM 1.000.23 (n6) 1.160.12 (n6)
IM 1.000.19 (n6) 1.200.61 (n6)
Values are presented as means  SD and n represents the number of rats.
*P  0.05 is considered statistically significant.
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segments investigated (Fig. 1C), and no subcellular shift was
observed in the phosphorylated fraction of AQP2 (Fig. 1A) nor
in the total amount of AQP2 in the segments investigated (data
not shown).
Characterization of an anti-phosphorylated-NKCC2 anti-
body. Since the antidiuretic effect and the increased urinary
osmolality observed in rats injected with rGH appeared to be
independent of increased collecting duct water permeability,
we decided to investigate the possibility that rGH could aug-
ment the osmotic driving force between the collecting duct
lumen and the interstitium. As NKCC2 is a key player in the
establishment of the osmotic gradient, the possibility that
NKCC2 was regulated in response to rGH administration was
investigated using an antibody specific to the Thr96 and Thr101-
phosphorylated NKCC2. Phosphorylation at these sites has
been shown to be necessary for increasing the maximal trans-
port activity of NKCC2 (15). To validate that the anti-phos-
phorylated-NKCC2 (p-NKCC2) antibody recognizes the phos-
phorylated epitope in NKCC2, peptide recognition and peptide
preabsorption were evaluated. The affinity-purified anti-p-
NKCC2 antibody selectively recognized the phosphorylated
peptide, but not the nonphosphorylated peptide on immuno-
blots (Fig. 2A). When homogenates from kidney ISOM were
subjected to differential centrifugation, SDS-PAGE, and im-
munoblotting, the anti-p-NKCC2 antibody produced a band
between 150 and 250 kDa in the 4,000- and 17,000-g pellets,
but not in the 200,000-g pellet (Fig. 2B). Thus, the anti-p-
NKCC2 antibody recognizes a band with a molecular weight
matching that reported for NKCC2 (34) and associates pre-
dominantly with the plasma membrane fraction. The localiza-
tion of the phosphorylated form of NKCC2 was determined on
immunohistochemical sections, using the anti-p-NKCC2 anti-
body. Staining was confined to the apical domains of the
epithelial cells in the TAL, where the phosphorylated form of
NKCC2 earlier has been found in mice (16) and in apical
domains of the macula densa (MD) cells (Fig. 3A). In addition
to the staining observed in the TAL/MD cells, the anti-p-
NKCC2 antibody revealed weak staining in the distal convo-
luted tubules. The staining was confined to very apical domains
of the DCT cells, where a narrow rim of labeling was evident
(Fig. 3A). On immunohistochemical sections, preabsorption of
the anti-p-NKCC2 antibody with the nonphosphorylated pep-
tide did not remove any significant amount of staining (Fig.
3B), whereas all staining was completely inhibited, when the
antibody was preabsorbed with the phosphorylated peptide
(Fig. 3C). Double labeling with anti-calbindin and anti-p-
NKCC2 confirmed that an anti-p-NKCC2 signal was present in
calbindin-positive cells (Fig. 3, D-F). Double labeling with
anti-NKCC2 and anti-p-NKCC2 (biotin conjugated) confirmed
the absence of NKCC2 signal in a fraction of the p-NKCC2-
positive cells (Fig. 3, G-H). We therefore conclude that the
anti-p-NKCC2 antibody selectively recognizes the phosphory-
lated epitope on NKCC2. Moreover, the immunohistochemical
labeling of the DCT indicates that the antibody also recognizes
the sodium chloride cotransporter (NCC), which is also known
to be phosphorylated on a homologous epitope (42). Since this
epitope is also conserved in NKCC1 (the secretory Na, K,
2Cl cotransporter), we investigated whether the antibody has
affinity for the phosphorylated form of NKCC1 in the parotid
gland (12). Indeed, the antibody labeled basolateral domains in
these cells (Fig. 3I), supporting that the antibody is specific
against the Thr96 and Thr101-phosphorylated form of NKCC2,
and corresponding phosphorylated epitopes in NKCC1 and
NCC in rats. Based on immunohistochemistry, the anti-p-
NKCC2 antibody appears to recognize similar epitopes in mice
and humans (data not shown).
Phosphorylated form of NKCC2 is localized exclusively in
the apical plasma membrane. Immunogold electron micros-
copy was used to investigate the subcellular localization of
p-NKCC2 and NKCC2. The anti-NKCC2 antibody labeled
apical membrane domains and intracellular domains in MD,
cortical TAL (cTAL), and mTAL (Fig. 4, A-C). In contrast,
incubation of kidney sections with the anti-p-NKCC2 antibody
showed immunogold labeling almost exclusively in or below
100 nm from the apical plasma membrane (Fig. 4, D-F). It was
not possible to investigate the labeling of the anti-p-NKCC2
antibody in the DCT, probably due to a lower affinity of the
antibody for the NCC-epitope or poor conservation of this
epitope in Lowicryl embedding.
Increased phosphorylation of NKCC2 in rGH-treated rats.
Semiquantitative immunoblotting using the anti-NKCC2 anti-
body and anti-p-NKCC2 antibodies showed a significant in-
crease in the abundance of phosphorylated NKCC2 and in the
total abundance of NKCC2 protein in samples from the CTX/
OSOM (Fig. 5A). In the ISOM, a significant increase in the
abundance of phosphorylated NKCC2 was observed in rats
injected with rGH (Fig. 5B), whereas no difference in the total
amount of NKCC2 protein was observed (Fig. 5B). To estimate
the degree of phosphorylation of NKCC2, the density mea-
sured using anti-p-NKCC2 was normalized to the density
measured using anti-NKCC2 on immunoblots by first probing
immunoblots with the anti-p-NKCC2 antibody, stripping them
in glycine buffer (pH  3), and reprobing them with anti-
NKCC2-antibody. In the CTX/OSOM, a 1.03-fold increase in
the degree of NKCC2 phosphorylation was found (P  0.80)
when normalized to the total amount of NKCC2 in the sample
(Fig. 5A). In the ISOM, a 2.42-fold increase was observed in
the rGH-treated group (P 0.03), when normalized to the total
amount of NKCC2 in the sample (Fig. 5B).
To confirm that phosphorylation was increased in the kidney
of rGH-injected rats, sections of paraffin-embedded rat kidneys
Fig. 2. Characterization of the anti-p-NKCC2 antibody using immunoblotting.
A: immunoblots of phospho and nonphospho peptides derived from the
NKCC2 sequence using the anti-p-NKCC2 antibody. B: anti-p-NKCC2 im-
munoblots of rat ISOM homogenates subjected to differential centrifugation:
4,000-g centrifugation pellet consists of larger cellular organelles, 17,000-g
centrifugation pellet consists largely of plasma membrane vesicles, and
200,000-g centrifugation pellet consists largely of intracellular vesicles.
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labeled with the anti-p-NKCC2 antibody were studied. In the
CTX and OSOM, no systematic difference in intensity of
labeling was observed between kidney sections from rGH-
injected and saline-injected rats (Fig. 6, A-B). In contrast, a
marked increase in anti-p-NKCC2 staining was seen in the
TAL of the ISOM of rGH-injected rats compared with controls
(Fig. 6, C-D). Note that in saline-injected rats, staining in the
cortical region is more intense than in the ISOM (Fig. 6, A and
C). This axial heterogeneity has also been reported earlier in
mice (16).
No change in the density of NKCC2 in the membrane of
mTAL cells in the ISOM. Using light microscopy, no change in
the subcellular localization of NKCC2 in the CTX, OSOM, and
ISOM was seen 5 h after rGH injection. Since it has been
shown that phosphorylation and apical targeting of NKCC2
increase in response to vasopressin (16), immunogold electron
microscopy was employed using the anti-NKCC2 antibody to
investigate whether a more subtle shift in NKCC2 was ob-
served in mTAL cells (Fig. 7). In three saline and three
rGH-injected rats, six cross sections of mTAL tubuli (ISOM)
were counted (60 pictures per animal). No difference in the
density of NKCC2 in the membrane was observed (4.3  0.47
vs. 5.0  0.74 gold particles/m membrane, P  0.23)
between rats injected with rGH or saline (Fig. 7).
rGH does not change Vte in isolated perfused mTAL. To
evaluate whether rGH directly increases NKCC2 activity, Vte
was measured in isolated microperfused mTAL (ISOM)
nephron segments. Peritubular addition of rGH (108 M) did
not change Vte (control 6.2  2.8 mV, rGH 5.8  1.8 mV,
recovery 5.5  1.6 mV, n  5; Fig. 8A), suggesting that the
effect of rGH is not direct. Therefore, it was investigated
whether peritubular addition of IGF-I (5 	 108 M) had an
effect on Vte. Again, no change in Vte was observed after
peritubular addition of IGF-I (control 7.5  3.7 mV, IGF-I
7.4 2.6 mV, recovery 6.8 2.7 mV, n 4; Fig. 8B). In both
sets of experiments, AVP (1010 M) was used as a positive
control in some of the tubules. Peritubular addition of AVP
induced a mean increase in Vte by 2.47  0.98 mV (P  0.05;
Fig. 8C).
DISCUSSION
The results of the present study strongly suggest that the
antinatriuretic effect of GH is mediated by an increased phos-
phorylation level of NKCC2 in the mTAL of the ISOM and by
increasing expression of NKCC2 in the cTAL, which leads to
increased NaCl reabsorption by the TAL. This single effect
could account for the antidiuretic effect of GH, by increasing
the osmotic driving force for water reabsorption from the thin
descending limbs of the loop of Henle and the collecting ducts.
In response to acute administration of rGH, a decrease in the
urinary excretion of sodium, potassium, and chloride, and a
Fig. 3. Characterization of the anti-p-NKCC2 antibody
using immunohistochemistry. A-C: immunolabelings on
2-m rat kidney sections using the p-NKCC2 antibody
(A), preabsorbed with nonphosphopeptide (B), or phos-
phopeptide (C). Pictures from the CTX were obtained
through a 	25 objective, scale bars  50 m. Note
weak labeling in the distal convoluted tubule (DCT).
D-F: confocal laser microscopy of double-labeled rat
kidney sections using polyclonal anti-p-NKCC2 (D),
monoclonal anti-calbindin (E), and overlay (F). Pictures
were obtained through a 	63 objective, scale bars  25
m. G-H: confocal laser microscopy of double-labeled
rat kidney sections using anti-p-NKCC2 conjugated to
biotin (G) and anti-NKCC2 (H). I: anti-p-NKCC2 im-
munolabeling of rat parotid gland. Pictures were ob-
tained through a 	25 objective, scale bar  50 m. G,
glomerulus; cTAL, cortical thick ascending limb; MD,
macula densa; Aci, acinus cell.
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Fig. 4. Immunoelectron microscopy of cross-sections from macula densa (MD; A, D) and thick ascending limb (TAL) cells in the cortex (B, E) and ISOM (C,
F). Labeling was visualized with 10-nm gold particles conjugated to antibodies against rabbit IgG. A-C: anti-NKCC2 antibody was associated with intracellular
vesicles (arrowheads) and the apical plasma membrane (arrows) of MD and TAL cells. D-F: labeling with the anti-p-NKCC2 antibody was almost exclusively
associated with the apical plasma membrane (arrows). Scale bars  500 nm.
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Fig. 5. Semiquantitative immunoblotting of
proteins using polyclonal anti-p-NKCC2 and
anti-NKCC2 antibodies. A: phosphorylation
levels and total expression of NKCC2 in
isolates from the CTX/OSOM of saline-
(filled bars) and rGH-injected (open bars)
rats. Graphs represent the average of the
band densities from rGH-injected group as
fractions of the average of the control group.
p-NKCC2: 1.0  0.23 vs. 1.8  0.30, P 
0.0003; NKCC2: 1.0  0.27 vs. 1.7  0.19,
P  0.0003. The p-NKCC2/NKCC2 ratio is
also depicted on the graph (1.00  0.25 vs.
1.03  0.21, P  0.80). B: phosphorylation
levels and total expression of NKCC2 in
protein isolates from the ISOM. p-NKCC2:
1.0  0.91 vs. 3.1  1.41, P  0.02;
NKCC2: 1.0  0.20 vs. 1.0  0.17, P 
0.83; p-NKCC2/NKCC2: 1.0  0.80 vs.
2.4  1.10, P  0.03. Data are expressed as
means  SD and represent n  6 for each
group. *P  0.05 is considered statistically
significant.
Fig. 6. Immunolabelings of p-NKCC2 in 2-m sections from kidneys of saline (A, C)- and rGH-injected rats (B, D). A-B: labeling with the anti-p-NKCC2
antibody in the CTX. C-D: labeling with the anti-p-NKCC2 antibody in the ISOM. A marked increase in p-NKCC2 immunostaining is observed in the ISOM
of rats injected with rGH. Pictures were obtained through a 	25 objective. Scale bar  50 m.
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decrease in urinary volume were observed in experimental
protocol 1 and 2. These findings are in accordance with earlier
studies using hGH in rats (32, 54, 56). Since rGH administra-
tion did not increase GFR, it can be concluded that the
electrolyte and water retention is due to increased tubular
reabsorption. This is also evident from the observed decreases
in the fractional excretions of electrolytes and water. In addi-
tion, an increase in urine osmolality was observed.
Two previous studies have investigated the clearance of
lithium during GH treatment (21, 31). However, both experi-
ments employed a protocol of chronic GH administration and
investigated the clearance of lithium after at least 5 days of GH
injections. In this experiment, focus was placed on finding
where in the renal tubule rGH exerted its acute antinatriuretic
and antidiuretic effect. The results from experimental protocol
2 show no difference in the fractional excretion of lithium.
Thus the estimated fractional excretion of sodium and water
from the proximal tubule remains unchanged after rGH injec-
tion. This suggests that the acute antidiuretic and antinatriuretic
effects observed after acute rGH administration occur in seg-
ments distal to the proximal tubule. This is supported by a
previous study, where volume absorption was unchanged in
perfused rabbit proximal convoluted tubules, after addition of
GH (50).
Phosphorylation sites have been described in the NKCC2,
the NKCC1, and the NCC cotransporters corresponding to
Thr96, Thr101, and Thr114 in rat NKCC2, Thr203, Thr208, and
Thr221 in rat NKCC1 and, Thr53, Thr58, Ser71 in rat NCC (12,
16, 42). The anti-p-NKCC2 antibody presented here is directed
against amino acids 91–106 in rat NKCC2 encompassing
phosphorylated threonines Thr96 and Thr101. The amino acid
sequence is highly conserved between the three cotransporters
and since the antibody recognizes epitopes in the apical mem-
branes of MD/TAL cells, basolateral domains of the parotid
gland as well as an epitope in the apical domains of DCT cells,
it seems able to recognize the phosphorylated forms of both
NKCC2, NKCC1, and NCC. Although the antibody labels the
apical domains of the DCT where NCC is found by immuno-
histochemistry, quantification of NCC phosphorylation is not
possible by immunoblotting, since the antibody has a much
higher affinity for p-NKCC2 as evaluated by immunohisto-
chemistry.
A significant increase in phosphorylated NKCC2 was seen
in response to an rGH injection. The increase in NKCC2
phosphorylation coincided with an increased reabsorption of
electrolytes and water after rGH injection. Gimenez and For-
bush (15) provided evidence for the involvement of Thr96,
Thr101, and Thr114 in the regulation of NKCC2 cotransport
Fig. 7. Immunogold electron microscopy using the anti-NKCC2 antibody was
employed to investigate the density of immunogold-labeled NKCC2 transport-
ers in the apical membrane of medullary TAL (mTAL) cells (ISOM). Hori-
zontal bars in the graph denote the group average, determined as gold particles
per membrane length per animal (n  3). Each data point in the figure
represents the average number of gold particles per micrometer apical mem-
brane in a single tubular cross section.
Fig. 8. Transepithelial voltage (Vte) was measured in isolated microperfused mTALs. A: changes in Vte in response to peritubular addition of 108 M rGH. B:
changes in Vte in response to peritubular addition of 5 	 108 M IGF-I. Individual results obtained with 5 (rGH) or 4 (IGF-I) independent tubules are displayed.
Each tubule was studied during 3 successive periods [control (CON), experimental (rGH or IGF-I), and recovery (REC)]. C: changes in Vte in response to
peritubular addition of 1010 M AVP. Lines connect paired measurements made in same tubule. Mean values of Vte appear in text.
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activity during exposure to hypertonic media in Xenopus laevis
oocytes. They found that deletion of the three phosphorylation
sites on NKCC2 completely abolished the increased ion trans-
port normally observed during exposure to hypertonic media.
However, as both the interstitial and luminal osmolality in the
ISOM changes in response to hydration status, it is difficult to
envision the effect of these phosphorylations in response to
hypertonicity in the mammalian kidney. Results from mice
(16) and those of the present study show a low level of NKCC2
phosphorylation during basal conditions in the mTAL (ISOM).
This indicates that the basal activity of NKCC2 is enough to
maintain its function in the kidney under baseline conditions.
Assuming that phosphorylation of NKCC2 in the ISOM will
increase net transport rate of NKCC2, increased transepithelial
transport of NaCl and to some extent K into the interstitium
is expected. This could account for the increased reabsorption
of electrolytes observed in the rGH-injected groups. An in-
creased transport rate of NKCC2 in the mTAL would also
enhance the osmotic driving force into the interstitium, thus
augmenting water removal from the descending thin limbs and
the collecting ducts. Since no regulation of AQP2 in the
collecting duct and no change in the estimated proximal tubular
water reabsorption were found in response to rGH administra-
tion, the reduced urinary volume and increased urine osmola-
lity observed after rGH treatment appear to be entirely depen-
dent on an increase in the osmotic driving force for water
reabsorption.
From the data presented here, one cannot exclude a role for
NCC in the GH-mediated antinatriuresis and antidiuresis. Due
to the limitations of the antibody used (i.e., low affinity for the
epitope in the DCT), it was not possible to evaluate whether
phosphorylation of NCC changes in response to GH adminis-
tration. Recent evidence suggests that phosphorylation of NCC
greatly affects transport rate in the oocyte expression system
(48). If NCC is activated in our experiments, this would
contribute to the increased NaCl reabsorption and to the in-
creased water reabsorption, by decreasing electrolyte delivery
to the collecting duct (i.e., increase osmotic driving force).
Regulation of NKCC2 and NCC phosphorylation is medi-
ated by two serine/threonine kinases, Ste20-related proline
alanine-rich kinase (SPAK) and oxidative stress response ki-
nase (OSR1). The kinases have recently been linked to several
key processes including regulation of cation-coupled chloride
transport (42). Upstream kinases directly interacting with
SPAK and OSR1, the so-called “with no lysine (K)” kinases,
termed WNK kinases (42), have also been shown to play
important roles in renal electrolyte transport (64). The signal-
ing pathway mediating rGH-induced phosphorylation of
NKCC2 may be speculated to include activation of one or
several of these kinases.
Immunogold electron microscopy was used to determine the
exact subcellular localization of both NKCC2 (phosphorylated
and nonphosphorylated) as well as the phosphorylated fraction
of NKCC2. Labeling for NKCC2 was found in intracellular
vesicles and in the apical membrane as previously described
(45), whereas immunogold labeling for the phosphorylated
form of NKCC2 was restricted almost entirely to the apical
plasma membrane. This suggests that either phosphorylation of
NKCC2 is necessary for membrane insertion, as with the
AQP2 water channel (44), or that NKCC2 is only phosphory-
lated while in the membrane. Gimenez and Forbush (16) noted
that the phosphorylation level of NKCC2, and membrane
targeting, appeared to work independently, since the vasopres-
sin-induced increase in NKCC2 phosphorylation exceeded the
level of protein translocation. Additionally, cAMP administra-
tion has recently been reported to directly stimulate shuttling of
NKCC2 (47), while the effect on NKCC2 phosphorylation
level remains unknown. In the present study, no change in
density of NKCC2 in the apical plasma membrane was seen
after rGH administration. This may indicate that rGH injec-
tions did not lead to increased abundance of NKCC2 in the
plasma membrane. However, the possibility exists that the
apical surface area of the mTAL cells is increased following
rGH injections resulting in an increased number of NKCC2
molecules facing the luminal fluid, despite no detectable
changes in the density of NKCC2 molecules within the mem-
brane.
Both the GH and IGF-I receptor have been localized to the
TAL (6, 35), suggesting that the increase in phosphorylation of
NKCC2 seen after rGH injections could be mediated by direct
action of rGH or indirectly through IGF-1. Using isolated
perfused mTAL segments, we tested whether peritubular rGH
addition directly stimulates NKCC2 transport activity. How-
ever, no change in Vte was observed. Thus the effects of rGH
injections most likely rely on intermediate signaling pathways.
The classic secondary signaling pathway of GH is through
stimulation of IGF-I production. However, the experimental
conditions (duration and rGH dose) were chosen to avoid an
increased systemic IGF-I concentration, and the total plasma
IGF-I concentration was unchanged between the groups. Thus
the observed renal effects cannot simply be ascribed to changes
in total systemic IGF-I concentration. IGF-I can also be pro-
duced and act locally, in response to GH administration (5, 51).
In the present study, rGH injections resulted in increased IGF-I
mRNA content in the CTX/OSOM, but not in ISOM or IM,
suggesting an increased local cortical IGF-I production. There-
fore, we could not rule out that local IGF-I production may
mediate the effects of GH in the mTAL, assuming that IGF-I
produced in CTX/OSOM can act in the ISOM. However,
peritubular exposure of isolated perfused mTAL segments to
IGF-I did not change the Vte, suggesting that IGF-I does not
influence the transport rate of NKCC2, as would be expected if
IGF-I induced phosphorylation of NKCC2. It should be noted
that the observation of increased NKCC2 protein abundance in
CTX/OSOM, but not in ISOM, coincides with increased
amount of IGF-I mRNA found in CTX/OSOM, although no
causal relationship can be documented.
NKCC2 has previously been shown to be phosphorylated in
the mTAL after stimulation by AVP. Therefore, the effects
seen in this study could be mediated by an increased plasma
AVP concentration, if injection of rGH by an unknown mech-
anism results in increased plasma AVP concentrations. The
mTAL have a high sensitivity to vasopressin, and net reab-
sorption of NaCl is significantly stimulated by the hormone,
whereas the cTAL does not change NaCl transport in the
presence of AVP (65). A similar relationship is observed in
mice after acute vasopressin administration, where an increase
in the phosphorylation of NKCC2 is observed in the mTAL,
while the cTAL maintains a high basal level of NKCC2
phosphorylation, that is not altered after addition of AVP (16).
The same could be observed in this experiment; however, as
phosphorylation of Ser256 on AQP2 and changes in the sub-
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cellular distribution of the channel are a hallmark of vasopres-
sin action (7, 13, 46, 66), and since no changes were seen in the
phosphorylation level of AQP2 or in the degree of apical
targeting of AQP2, it seems unlikely that rGH injection in-
duces an increase in plasma AVP concentration.
Insulin has been shown to increase chloride flux in the
mTAL and could therefore contribute to the observed effects in
this study (29). However, no change in insulin levels was
observed, which is in good agreement with an earlier study of
rats made diabetic by partial depancreatization. In these ani-
mals, GH still induced significant decreases in urinary sodium
and potassium excretion, supporting that the antinatriuretic
effect of GH is insulin independent (18). Thus at present the
signaling pathways leading from rGH injection to increased
phosphorylation of NKCC2 in the ISOM cannot be identified
further.
The acute antinatriuretic and antidiuretic effects of GH, in
conjunction with the pulsatile secretion pattern of GH from
pituitary somatrophs, suggest a possible role for GH in the
circadian variations of urinary electrolyte and water excretion/
urinary concentration. This becomes apparent in perfused rat
kidneys, where GH accelerated volume absorption was ob-
served at concentrations as low as 3.5 nM, with half-maximal
effect at 12 nM. The authors note that this is within the range
of the GH concentrations achieved during episodic GH surges
(62). Earlier studies have shown that a subcutaneous injection
of 2–4 mg hGH induces a progressive incline in plasma hGH
concentration during the first hour in female rats, a maximal
serum concentration is reached after 2 h with a decline after4
h, following a bell-shaped curve (33). In female rats, episodic
surges can reach as much as 3.64 	 108 M GH (9, 55),
suggesting that the dose used in this study results in the
expected physiological level obtained during a GH peak in
female rats, although for a prolonged period of time. Despite
the clear effect on NKCC2 phosphorylation documented in this
study, the acute effects of rGH do not appear to be directly
mediated by the hormone acting on the mTAL. However,
distinct increases in renal sodium and water reabsorption are
observed, suggesting a perhaps more central role for GH in
renal electrolyte and water homeostasis.
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